Last reviewed · How we verify
Zilbrix™
Zilbrix inhibits the activity of a specific enzyme.
Zilbrix inhibits the activity of a specific enzyme. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Zilbrix™ |
|---|---|
| Also known as | DTPw-HBV Kft |
| Sponsor | GlaxoSmithKline |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting this enzyme, Zilbrix helps to reduce the levels of a certain substance in the body, which in turn helps to manage the symptoms of a specific condition.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
- Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ (PHASE3)
- Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers (PHASE2)
- Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants (PHASE3)
- Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |